Cargando…

MDMA for the Treatment of Negative Symptoms in Schizophrenia

The profound economic burden of schizophrenia is due, in part, to the negative symptoms of the disease, which can severely limit daily functioning. There is much debate in the field regarding their measurement and classification and there are no FDA-approved treatments for negative symptoms despite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arnovitz, Mitchell D., Spitzberg, Andrew J., Davani, Ashkhan J., Vadhan, Nehal P., Holland, Julie, Kane, John M., Michaels, Timothy I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225098/ https://www.ncbi.nlm.nih.gov/pubmed/35743326 http://dx.doi.org/10.3390/jcm11123255

Ejemplares similares

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy
por: Feduccia, Allison A., et al.
Publicado: (2020)

NEGATIVE SYMPTOMS AND NEGATIVE SCHIZOPHRENIA
por: Chaturvedi, S.K., et al.
Publicado: (1984)

A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 2: Negative Symptoms in Schizophrenia [Podcast]
por: Racher, Matthew, et al.
Publicado: (2023)

Psychotherapy-supported MDMA treatment for PTSD
por: Krystal, John H., et al.
Publicado: (2021)

Acute Effects of Methylphenidate, Modafinil, and MDMA on Negative Emotion Processing
por: Schmidt, André, et al.
Publicado: (2017)

Attenuated Psychotic Symptoms in Adolescents With Chronic Cannabis and MDMA Use
por: Wiedmann, Melina, et al.
Publicado: (2022)

Methaemoglobinemia Induced by MDMA?
por: Verhaert, L. L. W.
Publicado: (2011)

Extasis (MDMA) : un abordaje comprehensivo /
por: Bobes García, Julio
Publicado: (1998)

NEGATIVE SYMPTOMS IN SCHIZOPHRENIA AND DEPRESSION
por: Chaturvedi, S.K., et al.
Publicado: (1985)

Negative symptoms in schizophrenia
por: Mitra, Sayantanava, et al.
Publicado: (2016)

MDMA-assisted psychotherapy for the treatment of PTSD
por: Reiff, Collin M., et al.
Publicado: (2020)

MDMA for the treatment of misophonia, a proposal
por: Webb, Jadon, et al.
Publicado: (2022)

MDMA-induced indifference to negative sounds is mediated by the 5-HT(2A) receptor
por: Kuypers, K. P. C., et al.
Publicado: (2017)

EPA guidance on treatment of negative symptoms in schizophrenia
por: Galderisi, S., et al.
Publicado: (2021)

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy
por: Sottile, Robert J., et al.
Publicado: (2022)

Potential Psychiatric Uses for MDMA
por: Yazar‐Klosinski, BB, et al.
Publicado: (2017)

Malignant hyperpyrexia in an MDMA ("Ecstasy") abuser.
por: McCoy, E. P., et al.
Publicado: (1994)

MDMA Impairs Response to Water Intake in Healthy Volunteers
por: Baggott, Matthew J., et al.
Publicado: (2016)

THC Prevents MDMA Neurotoxicity in Mice
por: Touriño, Clara, et al.
Publicado: (2010)

Effects of MDMA on body temperature in humans
por: Liechti, Matthias E
Publicado: (2014)

Pharmacological effects of methylone and MDMA in humans
por: Poyatos, Lourdes, et al.
Publicado: (2023)

MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology
por: Sáez-Briones, P., et al.
Publicado: (2013)

How Postmortem Redistribution of MDMA in Acute Alcohol-MDMA Combined-Use Rats Change under Effects of Alcohol
por: Liang, Man, et al.
Publicado: (2017)

Tackling Negative Symptoms of Schizophrenia with Memantine
por: Paraschakis, Antonios
Publicado: (2014)

The Effects of Bupropion on Negative Symptoms in Schizophrenia
por: Yassini, Mojtaba, et al.
Publicado: (2014)

Clozapine: Improvement of Negative Symptoms of Schizophrenia
por: Khan, Afaque H, et al.
Publicado: (2017)

Treating Negative Symptoms in Schizophrenia: an Update
por: Remington, Gary, et al.
Publicado: (2016)

Primary and Secondary Negative Symptoms in Schizophrenia
por: Mosolov, Sergey N., et al.
Publicado: (2022)

Predictive biomarkers for negative symptoms in schizophrenia
por: Cakici, N., et al.
Publicado: (2021)

Management of cognitive and negative symptoms in schizophrenia
por: Maroney, Megan
Publicado: (2022)

Marker of schizophrenia with enduring negative symptoms
por: Dmitrieva, E., et al.
Publicado: (2022)

EPA guidance on assessment of negative symptoms in schizophrenia
por: Galderisi, S., et al.
Publicado: (2021)

Pharmacological Mechanisms Involved in Sensory Gating Disruption Induced by (±)-3,4-Methylene- Dioxymethamphetamine (MDMA): Relevance to Schizophrenia
por: Lee, Jaime, et al.
Publicado: (2020)

Psilocybin and MDMA reduce costly punishment in the Ultimatum Game
por: Gabay, Anthony S., et al.
Publicado: (2018)

COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population
por: Aytac, Hasan Mervan, et al.
Publicado: (2022)

Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
por: Davidson, Michael, et al.
Publicado: (2022)

Negative and Cognitive Symptoms of Schizophrenia: Are there Adequate Pharmacological Treatments?
por: Vasiliu, O.
Publicado: (2022)

Increased interleukin-1β levels following low dose MDMA induces tolerance against the 5-HT neurotoxicity produced by challenge MDMA
por: Mayado, Andrea, et al.
Publicado: (2011)

Negative symptoms and associated factors in older people with schizophrenia
por: Karoui, M., et al.
Publicado: (2023)

3,4-methylenedioxymethamphetamine (MDMA): current perspectives
por: Meyer, Jerrold S
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ciq5btqviabgsmp1b79hjtsjus